Cargando…

Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?

Biological therapies are an effective treatment for a range of immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis, psoriasis, and inflammatory bowel diseases. However, due to their high costs, considerable differences in their utilization exist across the world, even among...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baumgart, Daniel C., Misery, Laurent, Naeyaert, Sue, Taylor, Peter C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6447826/ https://www.ncbi.nlm.nih.gov/pubmed/30983996 http://dx.doi.org/10.3389/fphar.2019.00279

Ejemplares similares

Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies
por: Moorkens, Evelien, et al.
Publicado: (2016)

Editorial: Biological drugs and biosimilars in autoimmune diseases
por: Wajda, Anna, et al.
Publicado: (2023)

Addressing Inequality of Access to Biologics: What Is Your Role? A Patient (Advocate)’s Perspective on Biosimilars
por: Piggin, Maria M.
Publicado: (2022)

Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
por: Vandenplas, Yannick, et al.
Publicado: (2021)

Biosimilars in Pediatric Inflammatory Bowel Diseases: A Systematic Review and Real Life-Based Evidence
por: Dipasquale, Valeria, et al.
Publicado: (2022)

Efficacy and safety of adalimumab biosimilar (HS016) in inflammatory bowel disease from the real-world study
por: Wang, Fang, et al.
Publicado: (2023)

The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors
por: Fabiani, Claudia, et al.
Publicado: (2019)

Efficacy, safety and immunogenicity of etanercept biosimilars versus reference biologics in patients with rheumatoid arthritis: A meta-analysis
por: Hu, Rui, et al.
Publicado: (2023)

The Clinical Implications of Nocebo Effects for Biosimilar Therapy
por: Colloca, Luana, et al.
Publicado: (2019)

Triggering the Resolution of Immune Mediated Inflammatory Diseases: Can Targeting Leukocyte Migration Be the Answer?
por: Hopkin, Sophie J., et al.
Publicado: (2019)

“Biosimilar, so it looks alike, but what does it mean?” A qualitative study of Danish patients' perceptions of biosimilars
por: Varma, Meera, et al.
Publicado: (2022)

Nocebo in Biosimilars and Generics in Neurology: A Systematic Review
por: Spanou, Ioanna, et al.
Publicado: (2019)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

Switching Among Biosimilars: A Review of Clinical Evidence
por: Allocati, Eleonora, et al.
Publicado: (2022)

Biosimilar Use and Switching in Belgium: Avenues for Integrated Policymaking
por: Barbier, Liese, et al.
Publicado: (2022)

An international comparative analysis and roadmap to sustainable biosimilar markets
por: Alnaqbi, Khalid A., et al.
Publicado: (2023)

Systematic Review and Network Meta-Analysis: Comparative Efficacy and Safety of Biosimilars, Biologics and JAK1 Inhibitors for Active Crohn Disease
por: Wu, Guozhi, et al.
Publicado: (2021)

The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
por: Kim, HoUng, et al.
Publicado: (2020)

Biological patent thickets and delayed access to biosimilars, an American problem
por: Goode, Rachel, et al.
Publicado: (2022)

Pharmacoeconomic Evaluation of Cancer Biosimilars Worldwide: A Systematic Review
por: Huang, Hui-Yao, et al.
Publicado: (2020)

Perceptions About Biosimilar Medicines Among Belgian Patients in the Ambulatory Care
por: Vandenplas, Yannick, et al.
Publicado: (2022)

Creating China’s Biosimilar Drugs Regulatory System: A Calculated Approach
por: Yang, Jianhong, et al.
Publicado: (2022)

Comparison of clot lysis activity and biochemical properties of originator tenecteplase (Metalyse(®)) with those of an alleged biosimilar
por: Kliche, Werner, et al.
Publicado: (2014)

Biosimilar biological drugs in the treatment of inflammatory bowel diseases
por: Kaniewska, Magdalena, et al.
Publicado: (2019)

Attitudes of Australians with inflammatory arthritis to biologic therapy and biosimilars
por: Quinlivan, Alannah, et al.
Publicado: (2022)

Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure
por: Vogler, Sabine, et al.
Publicado: (2021)

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
por: Kanters, Tim A., et al.
Publicado: (2017)

Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis
por: Xu, Xinyi, et al.
Publicado: (2022)

Intensive Safety Monitoring of Rituximab (Biosimilar Novex(®) and the Innovator) in Pediatric Patients With Complex Diseases
por: Riva, Natalia, et al.
Publicado: (2022)

A Biosimilarity Study Between QX001S and Ustekinumab in Healthy Chinese Male Subjects
por: Gao, Lei, et al.
Publicado: (2021)

Factors influencing bioequivalence evaluation of insulin biosimilars based on a structural equation model
por: Shao, Huarui, et al.
Publicado: (2023)

Biologics and Biosimilars in Psoriasis
por: Ahmed, Sk Shahriar, et al.
Publicado: (2023)

Potential of Biosimilars to Increase Access to Biologics: Considerations for Advanced Practice Providers in Oncology
por: Tinsley, Sara M., et al.
Publicado: (2018)

Heme Cytotoxicity and the Pathogenesis of Immune-Mediated Inflammatory Diseases
por: Larsen, Rasmus, et al.
Publicado: (2012)

Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
por: Kim, Yujeong, et al.
Publicado: (2020)

The Expiry of Humira(®) Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures
por: Moorkens, Evelien, et al.
Publicado: (2021)

Comparison of BRICS-TM Countries' Biosimilar Regulatory Frameworks With Australia, Canada and Switzerland: Benchmarking Best Practices
por: Rahalkar, Hasumati, et al.
Publicado: (2021)

Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of CMAB807, a New Denosumab Biosimilar, in Healthy Chinese Subjects
por: Chen, Hanjing, et al.
Publicado: (2022)

Key concepts in biosimilar medicines: What physicians must know
por: Iskit, Alper B.
Publicado: (2022)

The Urgent Need for Management of Biological Samples and Data Accessibility in Latin America
por: Vargas, Rodrigo José, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hhalq6fi0cfu8pebe1j1048480